Proteomics-related biomarkers for HBV-associated hepatocellular carcinoma: Current status and future prospects

Future Virology

Volumn 7, Issue 2, 2012, Pages 161-171

  Feng, Huixing ^a   Zhang, Jianhua ^a   Tan, Jane Y L ^a   Sadrolodabaee, Laleh ^a   Chen, Wei Ning ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

angiogenesis; biomarker; cell metastasis; HBV; HCC; proteomics

Indexed keywords

CELL PROTEIN; TUMOR MARKER; VIRUS PROTEIN;

ANGIOGENESIS; CELL MIGRATION; DISEASE ASSOCIATION; DNA METHYLATION; HEPATITIS B; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MASS SPECTROMETRY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

HEPATITIS B VIRUS;

EID: 84863173017     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.148     Document Type: Review

References (65)

1. Michielsen P, Ho E. Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol. Belg. 74(1), 4-8 (2011).
2. Lee SW, Lee YM, Bae SK, Murakami S, Yun Y, Kim KW. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem. Biophys. Res. Commun. 268(2), 456-461 (2000). (Pubitemid 30119644)
3. Zhang X, Wei D, Yap Y, Li L, Guo S, Chen F. Mass spectrometry-based omics technologies in cancer diagnostics. Mass Spectrom. Rev. 26(3), 403-431 (2007). (Pubitemid 46750377)
4. Sun W, Zhong F, Zhi L, Zhou G, He F. Systematic -omics analysis of HBV-associated liver diseases. Cancer Lett. 286(1), 89-95 (2009).
5. Imai K, Koshiyama A, Nakata K. Towards clinical proteomics analysis. Biomed. Chromatogr. 25(1-2), 59-64 (2011).
6. Chiou SH, Wu CY. Clinical proteomics: current status, challenges, and future perspectives. Kaohsiung J. Med. Sci. 27(1), 1-14 (2011).
7. Li C, Hong Y, Tan YX et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics 3(4), 399-409 (2004). (Pubitemid 38702092)
8. Sui J, Zhang J, Tan TL, Ching CB, Chen WN. Comparative proteomics analysis of vascular smooth muscle cells incubated with S- and R-enantiomers of atenolol using iTRAQ-coupled two-dimensional LC-MS/MS. Mol. Cell. Proteomics 7(6), 1007-1018 (2008). (Pubitemid 351943949)
9. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3(12), 1154-1169 (2004).
10. Griffiths SD, Burthem J, Unwin RD et al. The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol. Biotechnol. 36(2), 81-89 (2007). (Pubitemid 350135924)
11. Feng H, Li X, Niu D, Chen WN. Protein profile in HBx transfected cells: a comparative iTRAQ-coupled 2D LC-MS/MS analysis. J. Proteomics 73(8), 1421-1432 (2010).
12. Tong A, Wu L, Lin Q et al. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 8(10), 2012-2023 (2008). (Pubitemid 351775781)
13. Piantino P, Arrigoni A, Brunetto MR, Gindro T. Alpha-fetoprotein in hepatic pathology and hepatocarcinoma. J. Nucl. Med. Allied Sci. 33(3 Suppl.), 34-38 (1989).
14. Lok AS, Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 9(1), 110-115 (1989). (Pubitemid 19046312)
15. Sun S, Poon RT, Lee NP et al. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (
16. Feng JT, Liu YK, Song HY et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5(17), 4581-4588 (2005).
17. Sun Y, Zang Z, Xu X et al. Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. Int. J. Mol. Sci. 11(4), 1423-1433 (2010).
18. Kawakami T, Hoshida Y, Kanai F et al. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 5(16), 4287-4295 (2005). (Pubitemid 41626096)
19. Feng H, Wang M, Chen WN. iTRAQ-coupled 2D LC-MS/MS analysis of secreted proteome of HBV-replicating HepG2 cells: potential in biomarkers for prognosis of HCC. Curr. Microbiol. 61(4), 280-284 (2010).
20. Kalabay L, Jakab L, Prohaszka Z et al. Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur. J. Gastroenterol. Hepatol. 14(4), 389-394 (2002). (Pubitemid 34439037)
21. Yokoyama Y, Kuramitsu Y, Takashima M et al. Protein level of apolipoprotein E increased in human hepatocellular carcinoma. Int. J. Oncol. 28(3), 625-631 (2006).
22. Sun W, Xing B, Sun Y et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell. Proteomics 6(10), 1798-1808 (2007). (Pubitemid 350031681)
23. Steel LF, Shumpert D, Trotter M et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3(5), 601-609 (2003). (Pubitemid 36570251)
24. Henry L, Lavabre-Bertrand T, Vercambre L et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 58(6), 833-838 (2009).
25. Tong A, Gou L, Lau QC et al. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J. Proteome Res. 8(2), 1037-1046 (2009).
26. Hu Z, Zhang Z, Kim JW, Huang Y, Liang TJ. Altered proteolysis and global gene expression in hepatitis B virus X transgenic mouse liver. J. Virol. 80(3), 1405-1413 (2006). (Pubitemid 43134098)
27. Niu D, Sui J, Zhang J, Feng H, Chen WN. iTRAQ-coupled 2-D LC-MS/MS analysis of protein profile associated with HBV-modulated DNA methylation. Proteomics 9(15), 3856-3868 (2009).
28. Tan TL, Chen WN. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBx: potential in identification of early diagnostic markers for HCC. J. Clin. Virol. 33(4), 293-298 (2005). (Pubitemid 40982518)
29. Rivenbark AG, Coleman WB. The use of epigenetic biomarkers for preclinical detection of hepatocellular carcinoma: potential for noninvasive screening of high-risk populations. Clin. Cancer Res. 13(8), 2309-2312 (2007). (Pubitemid 46698577)
30. Narayan R, Gangadharan B, Hantz O et al. Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. J. Proteome Res. 8(1), 118-122 (2009).
31. Cui F, Wang Y, Wang J et al. The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice. Proteomics 6(2), 498-504 (2006). (Pubitemid 43208029)
32. Zhang J, Niu D, Sui J, Ching CB, Chen WN. Protein profile in hepatitis B virus replicating rat primary hepatocytes and HepG2 cells by iTRAQ-coupled 2-D LC-MS/MS analysis: insights on liver angiogenesis. Proteomics 9(10), 2836-2845 (2009).
33. Li L, Chen SH, Yu CH, Li YM, Wang SQ. Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J. Proteome Res. 7(2), 611-620 (2008). (Pubitemid 351294023)
34. Xie HY, Cheng J, Xing CY et al. Evaluation of hepatitis B viral replication and proteomic analysis of HepG2.2.15 cell line after knockdown of HBx. Hepatobiliary Pancreat. Dis. Int. 10(3), 295-302 (2011).
35. Kalabay L, Graf L, Voros K et al. Human serum fetuin A/alpha2HS- glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores. BMC Gastroenterol. 7, 15 (2007).
36. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5(8), 2145-2154 (1991). (Pubitemid 21905847)
37. Ai J, Tang Q, Wu Y et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J. Natl Cancer Inst. 103(22), 1696-1712 (2011).
38. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 139(5), 871-890 (2009).
39. Husemann Y, Geigl JB, Schubert F et al. Systemic spread is an early step in breast cancer. Cancer Cell 13(1), 58-68 (2008). (Pubitemid 350309740)
40. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 18(10), 1123-1125 (2004).
41. Yu FL, Liu HJ, Lee JW, Liao MH, Shih WL. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J. Hepatol. 42(4), 520-527 (2005).
42. Ou DP, Tao YM, Tang FQ, Yang LY. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int. J. Cancer 120(6), 1208-1214 (2007).
43. Lara-Pezzi E, Serrador JM, Montoya MC et al. The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology 33(5), 1270-1281 (2001). (Pubitemid 32378227)
44. Grise F, Bidaud A, Moreau V. Rho GTPases in hepatocellular carcinoma. Biochim. Biophys. Acta 1795(2), 137-151 (2009).
45. Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 49(5), 1583-1594 (2009).
46. Tan TL, Feng Z, Lu YW, Chan V, Chen WN. Adhesion contact kinetics of HepG2 cells during Hepatitis B virus replication: involvement of SH3-binding motif in HBx. Biochim. Biophys. Acta 1762(8), 755-766 (2006). (Pubitemid 44293371)
47. Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J. Biol. Chem. 278(20), 17775-17784 (2003). (Pubitemid 36799381)
48. Tan TL, Fang N, Neo TL et al. Rac1 GTPase is activated by hepatitis B virus replication - involvement of HBx. Biochim. Biophys. Acta 1783(3), 360-374 (2008).
49. Wang SM, Ooi LL, Hui KM. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin. Cancer Res. 17(18), 6040-6051 (2011).
50. Gou L, Wang W, Tong A et al. Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma. J. Mol. Med. (Berl.) 89(8), 817-827 (2011).
51. Cheng J, Xie HY, Xu X et al. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 310(1), 35-45 (2011).
52. Ai J, Huang H, Lv X et al. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell. Physiol. Biochem. 27(3-4), 207-216 (2011).
53. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 131(1 Suppl.), S135-S141 (2002). (Pubitemid 34118629)
54. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 39(5), 1185-1195 (2004). (Pubitemid 38569038)
55. Vollmar B, Siegmund S, Menger MD. An intravital fluorescence microscopic study of hepatic microvascular and cellular derangements in developing cirrhosis in rats. Hepatology 27(6), 1544-1553 (1998). (Pubitemid 28264677)
56. Tanaka S, Wands JR, Arii S. Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis. J. Hepatol. 44(1), 233-235 (2006). (Pubitemid 41772539)
57. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. 7(9), 1041-1047 (2001). (Pubitemid 32937385)
58. Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow-up of five randomised trials. Lancet 376(9754), 1741-1750 (2010).
59. Yao M, Zhou W, Sangha S et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin. Cancer Res. 11(4), 1618-1628 (2005). (Pubitemid 40315247)
60. Su F, Theodosis CN, Schneider RJ. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J. Virol. 75(1), 215-225 (2001).
61. Foo SY, Nolan GP. NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet. 15(6), 229-235 (1999). (Pubitemid 29278676)
62. Moonen RM, Reyes I, Cavallaro G, Gonzalez-Luis G, Bakker JA, Villamor E. The T1405N carbamoyl phosphate synthetase polymorphism does not affect plasma arginine concentrations in preterm infants. PLoS One 5(5), E10792 (2010).
63. Schulz LC, Bahr JM. Glucose-6-phosphate isomerase is necessary for embryo implantation in the domestic ferret. Proc. Natl Acad. Sci. USA 100(14), 8561-8566 (2003). (Pubitemid 36842583)
64. Schepens B, Tinton SA, Bruynooghe Y, Beyaert R, Cornelis S. The polypyrimidine tract-binding protein stimulates HIF-1alpha IRES-mediated translation during hypoxia. Nucleic Acids Res. 33(21), 6884-6894 (2005). (Pubitemid 41830492)
65. Li WH, Miao XH, Qi ZT, Ni W, Zhu SY, Fang F. Proteomic analysis of differently expressed proteins in human hepatocellular carcinoma cell lines HepG2 with transfecting hepatitis B virus X gene. Chin. Med. J. (Engl.) 122(1), 15-23 (2009).